Stocks
Evolent Health Financial Statements (EVH) |
||||||||||
| Evolent Healthsmart-lab.ru | % | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | 2024Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 23.02.2024 | 10.05.2024 | 09.08.2024 | 07.11.2024 | 08.11.2024 | 08.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 556.1 | 639.7 | 647.1 | 621.4 | 621.4 | 2 530 | |||
| Operating Income, bln rub | -21.4 | 5.83 | 9.46 | -16.3 | -16.3 | -17.3 | ||||
| EBITDA, bln rub | ? | -6.23 | 18.8 | 40.4 | -8.16 | 12.0 | 63.0 | |||
| Net profit, bln rub | ? | -33.4 | -17.3 | 1.60 | -31.2 | -23.1 | -70.1 | |||
| OCF, bln rub | ? | 89.4 | 4.91 | 21.4 | 18.7 | 18.7 | 63.7 | |||
| CAPEX, bln rub | ? | 6.05 | 5.35 | 7.11 | 6.29 | 6.29 | 25.0 | |||
| FCF, bln rub | ? | 83.3 | -0.438 | 14.3 | 12.4 | 12.4 | 38.6 | |||
| Dividend payout, bln rub | 5.16 | 5.08 | 5.07 | 5.13 | 5.13 | 20.4 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 317.5% | 0.00% | 0.00% | -29.1% | ||||
| OPEX, bln rub | 111.0 | 68.8 | 67.2 | 97.0 | 97.0 | 329.9 | ||||
| Cost of production, bln rub | 454.4 | 565.1 | 570.5 | 540.7 | 540.7 | 2 217 | ||||
| R&D, bln rub | 6.60 | 6.30 | 6.70 | 0.000 | 0.000 | 13.0 | ||||
| Interest expenses, bln rub | 12.2 | 6.00 | 6.00 | 6.01 | 6.01 | 24.0 | ||||
| Assets, bln rub | 2 680 | 2 644 | 2 475 | 2 502 | 2 502 | 2 502 | ||||
| Net Assets, bln rub | ? | 1 068 | 1 048 | 1 054 | 1 039 | 1 039 | 1 039 | |||
| Debt, bln rub | 644.8 | 824.4 | 819.9 | 635.2 | 635.2 | 635.2 | ||||
| Cash, bln rub | 192.8 | 216.7 | 121.3 | 112.9 | 112.9 | 112.9 | ||||
| Net debt, bln rub | 452.0 | 607.6 | 698.6 | 522.3 | 522.3 | 522.3 | ||||
| Ordinary share price, rub | 33.0 | 32.8 | 19.1 | 28.3 | 28.3 | 24.0 | ||||
| Number of ordinary shares, mln | 113.6 | 114.1 | 114.7 | 114.9 | 114.9 | 114.9 | ||||
| Market cap, bln rub | 3 752 | 3 743 | 2 193 | 3 248 | 3 248 | 2 753 | ||||
| EV, bln rub | ? | 4 204 | 4 350 | 2 891 | 3 771 | 3 771 | 3 276 | |||
| Book value, bln rub | -801 | -800 | -774 | -795 | -795 | -795 | ||||
| EPS, rub | ? | -0.29 | -0.15 | 0.01 | -0.27 | -0.20 | -0.61 | |||
| FCF/share, rub | 0.73 | 0.00 | 0.12 | 0.11 | 0.11 | 0.34 | ||||
| BV/share, rub | -7.05 | -7.01 | -6.75 | -6.93 | -6.93 | -6.93 | ||||
| EBITDA margin, % | ? | -1.12% | 2.94% | 6.25% | -1.31% | 1.92% | 2.49% | |||
| Net margin, % | ? | -6.01% | -2.70% | 0.25% | -5.03% | -3.72% | -2.77% | |||
| FCF yield, % | ? | 3.03% | 3.48% | 6.88% | 3.37% | 3.37% | 1.40% | |||
| ROE, % | ? | -10.6% | -10.5% | -7.06% | -7.73% | -6.95% | -6.74% | |||
| ROA, % | ? | -4.22% | -4.17% | -3.01% | -3.21% | -2.89% | -2.80% | |||
| P/E | ? | -33.2 | -33.9 | -29.5 | -40.4 | -45.0 | -39.3 | |||
| P/FCF | 33.0 | 28.7 | 14.5 | 29.6 | 29.6 | 71.3 | ||||
| P/S | ? | 1.91 | 1.72 | 0.93 | 1.32 | 1.32 | 1.09 | |||
| P/BV | ? | -4.68 | -4.68 | -2.83 | -4.08 | -4.08 | -3.46 | |||
| EV/EBITDA | ? | 1 781 | 74.3 | 40.5 | 40.0 | 58.0 | 52.0 | |||
| Debt/EBITDA | 191.5 | 10.4 | 9.77 | 5.54 | 8.04 | 8.29 | ||||
| R&D/CAPEX, % | 109.1% | 117.8% | 94.3% | 0.00% | 0.00% | 51.9% | ||||
| CAPEX/Revenue, % | 1.09% | 0.84% | 1.10% | 1.01% | 1.01% | 0.99% | ||||
| Evolent Health shareholders | ||||||||||
